New hope for uveitis: Anti-Inflammatory drug tested in chinese patients
NCT ID NCT07663331
First seen Jun 24, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This study tests the drug adalimumab (Tebiovio®) in 30 adults with non-infectious uveitis, an inflammatory eye disease. The goal is to see if the drug can control inflammation and prevent treatment failure. Participants will receive injections and be monitored for up to 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adalimumab (a drug that blocks inflammation)
- What this could lead to
- If successful, this could provide a new treatment option for adults with non-infectious uveitis, helping control inflammation and prevent vision loss.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The drug may not work for all patients and can have side effects like increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT NON-INFECTIOUS UVEITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Eye Hospital
RECRUITINGTianjin, Tianjin Municipality, 300384, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.